Proteomics

Dataset Information

0

XPO1 is a critical player for Bortezomib resistance in Multiple Myeloma: A quantitative proteomic approach


ABSTRACT: Among the blood cancers, 13% mortality is caused by Multiple myeloma (MM) type of haematological malignancy. In spite of therapeutic advances in chemotherapy treatment, still MM remains an incurable disease is mainly due to emergence of chemoresistance. At present time, FDA approved bortezomib is the first line drug for MM treatment. However, like other chemotherapy, MM patients are acquiring resistance against bortezomib. The present study aims to identify and validate bortezomib resistant protein targets in MM using iTRAQ and label free quantitative proteomic approaches. 125 differentially expressed proteins were commonly found in both approaches with similar differential expression pattern. XPO1 protein was selected for further validation as its significant high expression was observed in both iTRAQ and label free analysis. Bioinformatic analysis of these common differentially expressed proteins showed a clear cluster of proteins such as SMC1A, RCC2, CSE1, NUP88, NUP50, TPR, HSPA14, DYNLL1, RAD21 and RANBP2 being associated with XPO1. Functional studies like cell count assay, flow cytometry assay and soft agar assay proved that XPO1 knock down in RPMI 8226R cell line results in re-sensitization to bortezomib drug

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture, Plasma Cell

DISEASE(S): Multiple Myeloma

SUBMITTER: Srikanth Rapole  

LAB HEAD: Srikanth Rapole

PROVIDER: PXD013859 | Pride | 2019-09-09

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
MM_RPMI_DR_ITRAQ_01.raw Raw
MM_RPMI_DR_ITRAQ_02.raw Raw
MM_RPMI_DR_ITRAQ_03.raw Raw
MM_RPMI_DR_ITRAQ_04.raw Raw
MM_RPMI_DR_ITRAQ_05.raw Raw
Items per page:
1 - 5 of 18
altmetric image

Publications

XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach.

Chanukuppa Venkatesh V   Paul Debasish D   Taunk Khushman K   Chatterjee Tathagata T   Sharma Sanjeevan S   Kumar Saravanan S   Santra Manas K MK   Rapole Srikanth S  

Journal of proteomics 20190826


Among the blood cancers, 13% mortality is caused by Multiple myeloma (MM) type of hematological malignancy. In spite of therapeutic advances in chemotherapy treatment, still MM remains an incurable disease is mainly due to emergence of chemoresistance. At present time, FDA approved bortezomib is the first line drug for MM treatment. However, like other chemotherapy, MM patients are acquiring resistance against bortezomib. The present study aims to identify and validate bortezomib resistant prote  ...[more]

Similar Datasets

2014-05-19 | E-GEOD-49482 | biostudies-arrayexpress
2015-10-29 | E-GEOD-62821 | biostudies-arrayexpress
2014-05-19 | E-GEOD-49483 | biostudies-arrayexpress
2014-03-13 | E-GEOD-55818 | biostudies-arrayexpress
2016-01-05 | E-GEOD-76471 | biostudies-arrayexpress
2014-08-01 | E-MTAB-2666 | biostudies-arrayexpress
2014-03-13 | GSE55818 | GEO
2021-10-01 | GSE159426 | GEO
2010-10-20 | E-GEOD-24522 | biostudies-arrayexpress
2022-02-21 | MTBLS3487 | MetaboLights